Balversa (erdafitinib) — United Healthcare
Cholangiocarcinoma
Preferred products
- Lytgovi (futibatinib)
- Pemazyre (pemigatinib)
Initial criteria
- Diagnosis of cholangiocarcinoma
- Disease is one of the following: unresectable OR metastatic
- Presence of FGFR2 genetic alterations
- Disease has progressed on or after both of the following: Lytgovi (futibatinib) AND Pemazyre (pemigatinib)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Balversa therapy
Approval duration
12 months